Rhumbline Advisers Medicinova Inc Transaction History

Rhumbline Advisers

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$3.76 - $5.14 $184,461 - $252,163	-49,059 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$4.81 - $8.74 $9,812 - $17,829	-2,040 Reduced 3.99%	49,059 $248,000
Q4 2020 Feb 10, 2021	BUY	$5.03 - $6.31 $15,844 - $19,876	3,150 Added 6.57%	51,099 $269,000
Q3 2020 Nov 12, 2020	SELL	$4.67 - $11.0 $33,880 - $79,805	-7,255 Reduced 13.14%	47,949 $251,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $7.06 $6,762 - $15,602	2,210 Added 4.17%	55,204 $299,000
Q4 2019 Feb 05, 2020	BUY	$6.48 - $8.76 $1,814 - $2,452	280 Added 0.53%	52,994 $357,000
Q3 2019 Oct 23, 2019	SELL	$7.7 - $10.42 $3,080 - $4,168	-400 Reduced 0.75%	52,714 $419,000
Q2 2019 Aug 14, 2019	BUY	$8.29 - $13.22 $13,147 - $20,966	1,586 Added 3.08%	53,114 $511,000
Q1 2019 May 01, 2019	SELL	$6.82 - $10.27 $9,207 - $13,864	-1,350 Reduced 2.55%	51,528 $427,000
Q4 2018 Jan 31, 2019	BUY	$7.65 - $12.83 $132,230 - $221,766	17,285 Added 48.56%	52,878 $432,000
Q3 2018 Nov 07, 2018	SELL	$7.06 - $12.49 $16,591 - $29,351	-2,350 Reduced 6.19%	35,593 $445,000
Q2 2018 Aug 06, 2018	BUY	$7.96 - $13.23 $41,017 - $68,174	5,153 Added 15.72%	37,943 $302,000
Q1 2018 May 02, 2018	BUY	$6.6 - $13.91 $18,282 - $38,530	2,770 Added 9.23%	32,790 $335,000
Q4 2017 Feb 09, 2018	SELL	$5.89 - $7.21 $41,424 - $50,707	-7,033 Reduced 18.98%	30,020 $194,000
Q3 2017 Nov 06, 2017	BUY	$4.43 - $6.58 $164,144 - $243,808	37,053	37,053 $236,000

5.13M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $97.1M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.